These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 16326808)

  • 21. Striatal oligodendrogliogenesis and neuroblast recruitment are increased in the R6/2 mouse model of Huntington's disease.
    McCollum MH; Leon RT; Rush DB; Guthrie KM; Wei J
    Brain Res; 2013 Jun; 1518():91-103. PubMed ID: 23623813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease.
    Guo Z; Rudow G; Pletnikova O; Codispoti KE; Orr BA; Crain BJ; Duan W; Margolis RL; Rosenblatt A; Ross CA; Troncoso JC
    Mov Disord; 2012 Sep; 27(11):1379-86. PubMed ID: 22975850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PARP-1 Inhibition Is Neuroprotective in the R6/2 Mouse Model of Huntington's Disease.
    Cardinale A; Paldino E; Giampà C; Bernardi G; Fusco FR
    PLoS One; 2015; 10(8):e0134482. PubMed ID: 26252217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 'Super-Enrichment' Reveals Dose-Dependent Therapeutic Effects of Environmental Stimulation in a Transgenic Mouse Model of Huntington's Disease.
    Mazarakis NK; Mo C; Renoir T; van Dellen A; Deacon R; Blakemore C; Hannan AJ
    J Huntingtons Dis; 2014; 3(3):299-309. PubMed ID: 25300333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Striatal potassium channel dysfunction in Huntington's disease transgenic mice.
    Ariano MA; Cepeda C; Calvert CR; Flores-Hernández J; Hernández-Echeagaray E; Klapstein GJ; Chandler SH; Aronin N; DiFiglia M; Levine MS
    J Neurophysiol; 2005 May; 93(5):2565-74. PubMed ID: 15625098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice.
    van Dellen A; Welch J; Dixon RM; Cordery P; York D; Styles P; Blakemore C; Hannan AJ
    Neuroreport; 2000 Nov; 11(17):3751-7. PubMed ID: 11117485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human multipotent stromal cells (MSCs) increase neurogenesis and decrease atrophy of the striatum in a transgenic mouse model for Huntington's disease.
    Snyder BR; Chiu AM; Prockop DJ; Chan AW
    PLoS One; 2010 Feb; 5(2):e9347. PubMed ID: 20179764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease.
    Samadi P; Boutet A; Rymar VV; Rawal K; Maheux J; Kvann JC; Tomaszewski M; Beaubien F; Cloutier JF; Levesque D; Sadikot AF
    Genes Brain Behav; 2013 Feb; 12(1):108-24. PubMed ID: 23006318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Limbic neurogenesis/plasticity in the R6/2 mouse model of Huntington's disease.
    Phillips W; Morton AJ; Barker RA
    Neuroreport; 2006 Oct; 17(15):1623-7. PubMed ID: 17001281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.
    Milnerwood AJ; Kaufman AM; Sepers MD; Gladding CM; Zhang L; Wang L; Fan J; Coquinco A; Qiao JY; Lee H; Wang YT; Cynader M; Raymond LA
    Neurobiol Dis; 2012 Oct; 48(1):40-51. PubMed ID: 22668780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Solid Lipid Curcumin Particles Protect Medium Spiny Neuronal Morphology, and Reduce Learning and Memory Deficits in the YAC128 Mouse Model of Huntington's Disease.
    Gharaibeh A; Maiti P; Culver R; Heileman S; Srinageshwar B; Story D; Spelde K; Paladugu L; Munro N; Muhn N; Kolli N; Rossignol J; Dunbar GL
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dopaminergic manipulations and its effects on neurogenesis and motor function in a transgenic mouse model of Huntington's disease.
    Choi ML; Begeti F; Oh JH; Lee SY; O'Keeffe GC; Clelland CD; Tyers P; Cho ZH; Kim YB; Barker RA
    Neurobiol Dis; 2014 Jun; 66():19-27. PubMed ID: 24561069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibroblast Growth Factor 9 Suppresses Striatal Cell Death Dominantly Through ERK Signaling in Huntington's Disease.
    Yusuf IO; Cheng PH; Chen HM; Chang YF; Chang CY; Yang HI; Lin CW; Tsai SJ; Chuang JI; Wu CC; Huang BM; Sun HS; Yang SH
    Cell Physiol Biochem; 2018; 48(2):605-617. PubMed ID: 30021209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Purmorphamine increases DARPP-32 differentiation in human striatal neural stem cells through the Hedgehog pathway.
    El-Akabawy G; Medina LM; Jeffries A; Price J; Modo M
    Stem Cells Dev; 2011 Nov; 20(11):1873-87. PubMed ID: 21345011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abnormalities of neurogenesis in the R6/2 mouse model of Huntington's disease are attributable to the in vivo microenvironment.
    Phillips W; Morton AJ; Barker RA
    J Neurosci; 2005 Dec; 25(50):11564-76. PubMed ID: 16354914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model.
    Squitieri F; Di Pardo A; Favellato M; Amico E; Maglione V; Frati L
    J Cell Mol Med; 2015 Nov; 19(11):2540-8. PubMed ID: 26094900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intranasal Administration of Mesenchymal Stem Cells Ameliorates the Abnormal Dopamine Transmission System and Inflammatory Reaction in the R6/2 Mouse Model of Huntington Disease.
    Yu-Taeger L; Stricker-Shaver J; Arnold K; Bambynek-Dziuk P; Novati A; Singer E; Lourhmati A; Fabian C; Magg J; Riess O; Schwab M; Stolzing A; Danielyan L; Nguyen HHP
    Cells; 2019 Jun; 8(6):. PubMed ID: 31208073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GABAergic neurons from mouse embryonic stem cells possess functional properties of striatal neurons in vitro, and develop into striatal neurons in vivo in a mouse model of Huntington's disease.
    Shin E; Palmer MJ; Li M; Fricker RA
    Stem Cell Rev Rep; 2012 Jun; 8(2):513-31. PubMed ID: 21720791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral treatment with the herbal formula B401 protects against aging-dependent neurodegeneration by attenuating oxidative stress and apoptosis in the brain of R6/2 mice.
    Wang SE; Lin CL; Hsu CH; Sheu SJ; Wu CH
    Clin Interv Aging; 2015; 10():1825-37. PubMed ID: 26609226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human iPSC-derived neural precursor cells differentiate into multiple cell types to delay disease progression following transplantation into YAC128 Huntington's disease mouse model.
    Park HJ; Jeon J; Choi J; Kim JY; Kim HS; Huh JY; Goldman SA; Song J
    Cell Prolif; 2021 Aug; 54(8):e13082. PubMed ID: 34152047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.